SCHEMBL29568623

SCHEMBL29568623

COC(=O)c1ccc(Br)nc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.65
KDM4E B2RXH2 3/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
ALDH1A1 P00352 4/20 0.50
CA1 P00915 3/20 0.48
CA2 P00918 3/20 0.48
CA12 O43570 2/20 0.48
CA7 P43166 2/20 0.48
CA9 Q16790 2/20 0.48
CA14 Q9ULX7 2/20 0.48
TDP1 Q9NUW8 1/20 0.48
MAPT P10636 3/20 0.47
RAB9A P51151 2/20 0.47
NPC1 O15118 1/20 0.47
KMT2A Q03164 1/20 0.47
TSHR P16473 1/20 0.45
NNMT P40261 1/20 0.44
XDH P47989 1/20 0.44
NOTUM Q6P988 1/20 0.44
LOXL2 Q9Y4K0 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL424411 1.00 MAPK1 (0.65) MAPK1KDM4EL3MBTL1ALDH1A1CA1
SCHEMBL3499765 0.86 DEGS1 (0.50) MAPK1KDM4EL3MBTL1RAB9ANPC1
SCHEMBL27444021 0.86 MAPK1 (0.49) MAPK1KDM4EL3MBTL1ALDH1A1CA1
SCHEMBL27588541 0.82 MAPK1 (0.43) MAPK1KDM4EL3MBTL1ALDH1A1MAPT
SCHEMBL25267522 0.82 MAPK1 (0.45) MAPK1KDM4EL3MBTL1ALDH1A1CA1
SCHEMBL65277 0.81 NNMT (0.68) MAPK1KDM4EL3MBTL1ALDH1A1CA1
SCHEMBL1755302 0.81 MAPK1 (0.65) MAPK1KDM4EL3MBTL1ALDH1A1CA1
SCHEMBL1462391 0.80 CA12 (0.43) MAPK1KDM4EL3MBTL1CA1CA2
SCHEMBL31325031 0.80 CA12 (0.53) L3MBTL1ALDH1A1CA1CA2CA12
SCHEMBL2768265 0.80 CA12 (0.53) L3MBTL1ALDH1A1CA1CA2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4543858-A1 BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES Draupnir Bio ApS (DK) 2025-04-30 EP disclosed
WO-2024226875-A2 COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS INITIAL THERAPEUTICS, INC. (US) 2024-10-31 WO disclosed
EP-4423086-A1 TYK2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2024-09-04 EP disclosed
WO-2023247754-A1 BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES DRAUPNIR BIO APS (DK) 2023-12-28 WO disclosed
WO-2023076161-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-05-04 WO disclosed
EP-4055008-A1 CANCER TREATMENTS TARGETING CANCER STEM CELLS Remedy Plan, Inc. (US) 2022-09-14 EP disclosed
WO-2022165402-A1 INHIBITORS OF PROTEIN KINASE A BLUEPRINT MEDICINES CORPORATION (US) 2022-08-04 WO disclosed
EP-3976612-A1 NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 MANKIND PHARMA LTD (IN) 2022-04-06 EP disclosed